These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 28122379)

  • 21. Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications.
    Imperiale A; Moussallieh FM; Roche P; Battini S; Cicek AE; Sebag F; Brunaud L; Barlier A; Elbayed K; Loundou A; Bachellier P; Goichot B; Stratakis CA; Pacak K; Namer IJ; Taïeb D
    Neoplasia; 2015 Jan; 17(1):55-65. PubMed ID: 25622899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LncRNA expression and SDHB mutations in pheochromocytomas and paragangliomas.
    Li H; Hardin H; Zaeem M; Huang W; Hu R; Lloyd RV
    Ann Diagn Pathol; 2021 Dec; 55():151801. PubMed ID: 34461576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background.
    Fishbein L; Nathanson KL
    Cancer Genet; 2012; 205(1-2):1-11. PubMed ID: 22429592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel SDHB and TMEM127 Mutations in Patients with Pheochromocytoma/Paraganglioma Syndrome.
    Patócs A; Lendvai NK; Butz H; Liko I; Sapi Z; Szucs N; Toth G; Grolmusz VK; Igaz P; Toth M; Rácz K
    Pathol Oncol Res; 2016 Oct; 22(4):673-9. PubMed ID: 26960314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era.
    Pillai S; Gopalan V; Smith RA; Lam AK
    Crit Rev Oncol Hematol; 2016 Apr; 100():190-208. PubMed ID: 26839173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GROWTH RATE OF PARAGANGLIOMAS RELATED TO GERMLINE MUTATIONS OF THE SDHX GENES.
    Michałowska I; Ćwikła JB; Michalski W; Wyrwicz LS; Prejbisz A; Szperl M; Nieć D; Neumann HP; Januszewicz A; Pęczkowska M
    Endocr Pract; 2017 Mar; 23(3):342-352. PubMed ID: 27967220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma.
    Burnichon N; Vescovo L; Amar L; Libé R; de Reynies A; Venisse A; Jouanno E; Laurendeau I; Parfait B; Bertherat J; Plouin PF; Jeunemaitre X; Favier J; Gimenez-Roqueplo AP
    Hum Mol Genet; 2011 Oct; 20(20):3974-85. PubMed ID: 21784903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased SSTR2A and SSTR3 expression in succinate dehydrogenase-deficient pheochromocytomas and paragangliomas.
    Elston MS; Meyer-Rochow GY; Conaglen HM; Clarkson A; Clifton-Bligh RJ; Conaglen JV; Gill AJ
    Hum Pathol; 2015 Mar; 46(3):390-6. PubMed ID: 25554089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting pheochromocytoma/paraganglioma with polyamine inhibitors.
    Rai SK; Bril F; Hatch HM; Xu Y; Shelton L; Kalavalapalli S; Click A; Lee D; Beecher C; Kirby A; Kong K; Trevino J; Jha A; Jatav S; Kriti K; Luthra S; Garrett TJ; Guingab-Cagmat J; Plant D; Bose P; Cusi K; Hromas RA; Tischler AS; Powers JF; Gupta P; Bibb J; Beuschlein F; Robledo M; Calsina B; Timmers H; Taieb D; Kroiss M; Richter S; Langton K; Eisenhofer G; Bergeron R; Pacak K; Tevosian SG; Ghayee HK
    Metabolism; 2020 Sep; 110():154297. PubMed ID: 32562798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
    van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
    J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SDHC Promoter Methylation, a Novel Pathogenic Mechanism in Parasympathetic Paragangliomas.
    Bernardo-Castiñeira C; Valdés N; Sierra MI; Sáenz-de-Santa-María I; Bayón GF; Perez RF; Fernández AF; Fraga MF; Astudillo A; Menéndez R; Fernández B; Del Olmo M; Suarez C; Chiara MD
    J Clin Endocrinol Metab; 2018 Jan; 103(1):295-305. PubMed ID: 29126304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of maternal chromosome 11 is a signature event in SDHAF2, SDHD, and VHL-related paragangliomas, but less significant in SDHB-related paragangliomas.
    Hoekstra AS; Hensen EF; Jordanova ES; Korpershoek E; van der Horst-Schrivers AN; Cornelisse C; Corssmit EP; Hes FJ; Jansen JC; Kunst HP; Timmers HJ; Bateman A; Eccles D; Bovée JV; Devilee P; Bayley JP
    Oncotarget; 2017 Feb; 8(9):14525-14536. PubMed ID: 28099933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
    Zhang X; Wang X; Xu T; Zhong S; Shen Z
    Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetics and molecular pathogenesis of pheochromocytoma and paraganglioma.
    Galan SR; Kann PH
    Clin Endocrinol (Oxf); 2013 Feb; 78(2):165-75. PubMed ID: 23061808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options.
    Vicha A; Musil Z; Pacak K
    Curr Opin Endocrinol Diabetes Obes; 2013 Jun; 20(3):186-91. PubMed ID: 23481210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas.
    Korpershoek E; Favier J; Gaal J; Burnichon N; van Gessel B; Oudijk L; Badoual C; Gadessaud N; Venisse A; Bayley JP; van Dooren MF; de Herder WW; Tissier F; Plouin PF; van Nederveen FH; Dinjens WN; Gimenez-Roqueplo AP; de Krijger RR
    J Clin Endocrinol Metab; 2011 Sep; 96(9):E1472-6. PubMed ID: 21752896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice.
    Xekouki P; Szarek E; Bullova P; Giubellino A; Quezado M; Mastroyannis SA; Mastorakos P; Wassif CA; Raygada M; Rentia N; Dye L; Cougnoux A; Koziol D; Sierra Mde L; Lyssikatos C; Belyavskaya E; Malchoff C; Moline J; Eng C; Maher LJ; Pacak K; Lodish M; Stratakis CA
    J Clin Endocrinol Metab; 2015 May; 100(5):E710-9. PubMed ID: 25695889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loss of BAP1 in Pheochromocytomas and Paragangliomas Seems Unrelated to Genetic Mutations.
    Maffeis V; Cappellesso R; Nicolè L; Guzzardo V; Menin C; Elefanti L; Schiavi F; Guido M; Fassina A
    Endocr Pathol; 2019 Dec; 30(4):276-284. PubMed ID: 31734934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of SDHAF2 and SDHD in von Hippel-Lindau associated pheochromocytomas.
    Kugelberg J; Welander J; Schiavi F; Fassina A; Bäckdahl M; Larsson C; Opocher G; Söderkvist P; Dahia PL; Neumann HP; Gimm O
    World J Surg; 2014 Mar; 38(3):724-32. PubMed ID: 24322175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of the natural antisense hypoxia-inducible factor-1alpha transcript is associated with malignant pheochromocytoma/paraganglioma.
    Span PN; Rao JU; Oude Ophuis SB; Lenders JW; Sweep FC; Wesseling P; Kusters B; van Nederveen FH; de Krijger RR; Hermus AR; Timmers HJ
    Endocr Relat Cancer; 2011 Jun; 18(3):323-31. PubMed ID: 21422080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.